Skip to content
DataLookout
Menu

TER-EYENCT06905834

Evaluation of Allogenic Mesenchymal Stem Cell (MSC) Injection Therapy for Refractory Graft-versus-Host Disease (GVHD) Unresponsive to Conventional Treatments

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved at least 1 year 6 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Jun 2027 to Jan 2029 Show 4 more changesShow less
    • Start date pushed from Oct 2026 to Dec 2026
    • Eligibility criteria expanded, about 16 words
    • Study completion pushed from Jun 2028 to Jun 2030
    • Secondary endpoints: details revised at 3 of 4 entries
  2. Notable Start date: May 2026 to Oct 2026v4
  3. Notable Start date: Jun 2025 to May 2026v3
  4. Notable Eligibility criteria expanded, about 7 words
    • Secondary endpoints: details revised at 3 of 4 entries
    v2
  5. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Change in the integrity of the ocular surface
Timeframe: six and twelve months from start of treatment
Change in tear production
Timeframe: six and twelve months from start of treatment
Change in the degree of conjunctival hyperemia
Timeframe: six and twelve months from start of treatment
Change in the parameters related to the Meibomian glands
Timeframe: six and twelve months from start of treatment
Change in any of the findings in the central cornea
Timeframe: six and twelve months from start of treatment
Severity of eye disease measured by WFPRS (Wong-Baker Faces Pain Rating Scale)
Timeframe: six and twelve months from start of treatment
Severity of eye disease measured by Numerical Rating Scale (NRS)
Timeframe: six and twelve months from start of treatment
Severity of eye disease measured by Modified Symptom Assessment in Dry Eye Questionnaire (mSIDEQ)
Timeframe: six and twelve months from start of treatment
Severity of eye disease measured by Ocular Surface Disease Index (OSDI)
Timeframe: six and twelve months from start of treatment
Severity of eye disease measured by CDES-Q (Contact Lens Dry Eye Symptom Questionnaire)
Timeframe: six and twelve months from start of treatment

Secondary (4)

Rate of adverse events related to the administration of subconjunctival ASC injection.
Analysis of ocular marker expression in the administered ASCs
Analysis of the presence and concentration of inflammation-related molecules in tear and serum samples
Search for new biomarkers that can be used to objectively evaluate the progression of patients affected by EICRc with ocular involvement.

Arms and interventions

6.25 million ASCs / 2,5ml of Ringer Lactato + 1% of HSA.Experimental

6.25 million mesenchymal cells will be injected subconjunctivally into each subject in the group. These cells will be in a 2.5 mL suspension of Lactated Ringer's solution, to which 1% HSA will have been added beforehand.

12.5 million ASCs / 2,5 ml of Ringer Lactato + 1% of HSA.Experimental

12.5 million mesenchymal cells will be injected subconjunctivally into each subject in the group. These cells will be in a 2.5 mL suspension of Lactated Ringer's solution, to which 1% HSA will have been added beforehand.

Drugs: Subconjuntival injection of expanded allogenic adult adipose tissue-derived mesenchymal stem cells (ASC